Sanofi $SNY Shares Bought by Blume Capital Management Inc.

by · The Cerbat Gem

Blume Capital Management Inc. raised its position in Sanofi (NASDAQ:SNY – Free Report) by 315,725.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 25,266 shares of the company’s stock after acquiring an additional 25,258 shares during the period. Blume Capital Management Inc.’s holdings in Sanofi were worth $1,193,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Waterfront Wealth Inc. raised its stake in shares of Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after buying an additional 214 shares in the last quarter. HighPoint Advisor Group LLC grew its holdings in Sanofi by 2.3% during the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock worth $468,000 after acquiring an additional 226 shares during the period. HM Payson & Co. raised its position in Sanofi by 3.4% in the third quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock worth $342,000 after acquiring an additional 235 shares in the last quarter. Leonard Rickey Investment Advisors P.L.L.C. lifted its holdings in Sanofi by 4.7% in the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock valued at $252,000 after acquiring an additional 238 shares during the period. Finally, CreativeOne Wealth LLC boosted its position in shares of Sanofi by 2.8% during the 2nd quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock worth $434,000 after purchasing an additional 241 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SNY. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. HSBC reissued a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Sanofi presently has an average rating of “Hold” and a consensus target price of $62.67.

Get Our Latest Stock Analysis on SNY

Sanofi Trading Up 0.7%

Shares of SNY opened at $47.83 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.29. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The stock has a market cap of $116.66 billion, a price-to-earnings ratio of 13.29, a price-to-earnings-growth ratio of 1.24 and a beta of 0.45. The firm has a 50 day simple moving average of $47.91 and a 200-day simple moving average of $48.65.

About Sanofi

(Free Report)

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

Recommended Stories

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).